Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | AGER | Q15109 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | NAPRT | Q6XQN6 | 3/20 | 0.53 |
| ▸ | ASPH | Q12797 | 1/20 | 0.52 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.52 |
| ▸ | MYC | P01106 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CTSA | P10619 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1874614 | 0.98 | KDM4E (0.59) | KDM4EMAPTL3MBTL1ALDH1A1CYP3A4 | |
| 2-Picolinic Acid SCHEMBL18840037 | 0.88 | L3MBTL1 (0.67) | KDM4EMAPTL3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL27994859 | 0.83 | KDM4E (0.52) | KDM4EMAPTL3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL20054565 | 0.83 | KDM4E (0.45) | KDM4EMAPTL3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL27907920 | 0.81 | KDM4E (0.50) | KDM4EMAPTL3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL319270 | 0.81 | MAPT (0.49) | KDM4EMAPTL3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL1812108 | 0.81 | ALDH1A1 (0.45) | KDM4EMAPTL3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL15863495 | 0.81 | ALDH1A1 (0.47) | KDM4EMAPTL3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL20221424 | 0.81 | KDM4E (0.44) | KDM4EMAPTL3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL20385460 | 0.80 | KMT2A (0.52) | KDM4EMAPTL3MBTL1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 480 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117836306-A | Galactose glycoside derivatives as galectin-3 inhibitors | 株式会社蒂奥姆生物 | 2024-04-05 | — | — | CN | claimed |
| CN-116768285-A | Modification method of nickel-based layered positive electrode material surface and grain boundary for fluoride stabilized lithium ion battery | 中国科学院上海硅酸盐研究所 | 2023-09-19 | — | — | CN | claimed |
| EP-2755963-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-10-30 | — | — | EP | claimed |
| CN-108503581-A | A kind of synthetic method of the fluoro- 2- pyridines ethyl ketones of the bromo- 6- of 3- | 苏州康润医药有限公司 | 2018-09-07 | — | — | CN | claimed |
| CN-105130959-B | Pyrimidine derivatives PIM kinase inhibitors and preparation method thereof and the application in pharmacy | 上海吉铠医药科技有限公司 | 2018-08-03 | — | — | CN | claimed |
| CN-104136431-B | Pyridone and pyrimidone derivatives as plasma thromboplastin antecedent a inhibitor | 小野药品工业株式会社 | 2017-03-15 | — | — | CN | claimed |
| CN-103814021-B | Dihydroquinoline 2 ketone derivatives | 霍夫曼-拉罗奇有限公司 | 2016-12-21 | — | — | CN | claimed |
| EP-2511268-B1 | OXAZINE DERIVATIVE | SHIONOGI & CO (JP) | 2016-07-13 | — | — | EP | claimed |
| CN-104003934-B | The synthesis of the fluoro-2-pyridine carboxylic acid of the chloro-3-of 6- | XIHUA UNIVERSITY (CN) | 2016-04-13 | — | — | CN | claimed |
| US-9260408-B2 | Dihydroquinoline-2-one derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-02-16 | — | — | US | claimed |
| EP-2467368-A1 | 3-AMINO-5-PHENYL-5,6-DIHYDRO-2H-[1,4]OXAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-06-27 | — | — | EP | claimed |
| EP-2456763-A1 | OXAZINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2012-05-30 | — | — | EP | claimed |
| CN-102471293-A | Oxazine derivatives and their use as BACE inhibitors for the treatment of neurological disorders | NOVARTIS AG | 2012-05-23 | — | — | CN | claimed |
| CN-102421760-A | Dihydropyrimidinones useful as BACE2 inhibitors | HOFFMANN LA ROCHE | 2012-04-18 | — | — | CN | claimed |
| CN-101563328-B | substituted heteroaryl Pyridopyrimidinone derivatives | SANOFI AVENTIS | 2012-03-14 | — | — | CN | claimed |
| WO-2012006953-A1 | OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-01-19 | — | — | WO | claimed |
| WO-2010128058-A1 | DIHYDROPYRIMIDINONES FOR USE AS BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | claimed |
| US-20100286158-A1 | DIHYDROPYRIMIDINONES | HOFFMANN-LA ROCHE, INC. | 2010-11-11 | — | — | US | claimed |
| CN-101563328-A | Substituted heteroaryl pyridopyrimidinone derivatives | SANOFI AVENTIS (FR) | 2009-10-21 | — | — | CN | claimed |
| CN-101065377-A | Imidazo[1,2-a]pyridine compounds, compositions, uses and methods related thereto | FERRER INT (ES) | 2007-10-31 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286158-A1 | DIHYDROPYRIMIDINONES | BACE2, BACE1, PSEN2 | KDM4E 2548/4885MAPT 143/4885L3MBTL1 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.